IFF Pharma Solutions Brings Next-Gen Excipient Innovations to CPHI Japan 2025
IFF (NYSE:IFF) Pharma Solutions will showcase its innovative excipient technologies at CPHI Japan 2025, taking place April 9-11 at Tokyo Big Sight. The company will highlight three key product lines:
1. Oral Disintegrating Tablet (ODT) Solutions, featuring Ac-Di-Sol® super disintegrant for rapid dissolution
2. Controlled Release Portfolio, including METHOCEL™ HPMC, ETHOCEL™ Ethylcellulose for water-resistant coatings, and POLYOX™ Polyethylene Oxide for high-swell matrices
3. Low-Nitrite Solutions, including Avicel® PH LN and Low Nitrite METHOCEL™, designed to reduce nitrosamine formation risks in oral solid dosages and meet Japan's regulatory standards
IFF (NYSE:IFF) Pharma Solutions presenterà le sue innovative tecnologie per eccipienti al CPHI Japan 2025, che si svolgerà dal 9 all'11 aprile presso il Tokyo Big Sight. L'azienda metterà in evidenza tre linee di prodotti chiave:
1. Soluzioni per Compresse Orali Disintegranti (ODT), che presentano l'acido Ac-Di-Sol® come super disintegrante per una rapida dissoluzione.
2. Portafoglio di Rilascio Controllato, che include METHOCEL™ HPMC, ETHOCEL™ Etilecellulosa per rivestimenti resistenti all'acqua e POLYOX™ Ossido di Polietilene per matrici ad alta espansione.
3. Soluzioni a Basso Nitrito, comprese Avicel® PH LN e METHOCEL™ a Basso Nitrito, progettate per ridurre i rischi di formazione di nitrosamine nelle dosi solide orali e per soddisfare gli standard normativi giapponesi.
IFF (NYSE:IFF) Pharma Solutions presentará sus innovadoras tecnologías de excipientes en CPHI Japan 2025, que se llevará a cabo del 9 al 11 de abril en Tokyo Big Sight. La empresa destacará tres líneas de productos clave:
1. Soluciones para Tabletas Disintegrantes Orales (ODT), que presentan Ac-Di-Sol® como superdisintegrante para una rápida disolución.
2. Portafolio de Liberación Controlada, que incluye METHOCEL™ HPMC, ETHOCEL™ Etilecelulosa para recubrimientos resistentes al agua y POLYOX™ Óxido de Polietileno para matrices de alta expansión.
3. Soluciones de Bajo Nitrito, que incluyen Avicel® PH LN y METHOCEL™ de Bajo Nitrito, diseñadas para reducir los riesgos de formación de nitrosaminas en dosis sólidas orales y cumplir con los estándares regulatorios de Japón.
IFF (NYSE:IFF) 제약 솔루션은 CPHI Japan 2025에서 혁신적인 부형제 기술을 선보일 예정이며, 이 행사는 4월 9일부터 11일까지 도쿄 빅사이트에서 열립니다. 회사는 세 가지 주요 제품 라인을 강조합니다:
1. 구강 분해 정제(ODT) 솔루션, 빠른 용해를 위한 Ac-Di-Sol® 슈퍼 분해제를 특징으로 합니다.
2. 조절 방출 포트폴리오, 물 저항성 코팅을 위한 METHOCEL™ HPMC, ETHOCEL™ 에틸셀룰로오스 및 고팽창 매트릭스를 위한 POLYOX™ 폴리에틸렌 산화물을 포함합니다.
3. 저니트로사민 솔루션, Avicel® PH LN 및 저니트로사민 METHOCEL™을 포함하여, 경구 고형 제제에서 니트로사민 형성 위험을 줄이고 일본의 규제 기준을 충족하도록 설계되었습니다.
IFF (NYSE:IFF) Pharma Solutions présentera ses technologies innovantes d'excipients lors de CPHI Japan 2025, qui se tiendra du 9 au 11 avril au Tokyo Big Sight. L'entreprise mettra en avant trois lignes de produits clés :
1. Solutions de Comprimés Disintégrants Orales (ODT), avec Ac-Di-Sol® comme super disintégrant pour une dissolution rapide.
2. Portefeuille de Libération Contrôlée, incluant METHOCEL™ HPMC, ETHOCEL™ Éthylcellulose pour des revêtements résistants à l'eau, et POLYOX™ Oxyde de Polyéthylène pour des matrices à forte expansion.
3. Solutions à Faible Nitrite, y compris Avicel® PH LN et METHOCEL™ à Faible Nitrite, conçues pour réduire les risques de formation de nitrosamines dans les dosages solides oraux et répondre aux normes réglementaires japonaises.
IFF (NYSE:IFF) Pharma Solutions wird seine innovativen Hilfsstofftechnologien auf der CPHI Japan 2025 präsentieren, die vom 9. bis 11. April im Tokyo Big Sight stattfindet. Das Unternehmen wird drei wichtige Produktlinien hervorheben:
1. Oral Disintegrating Tablet (ODT) Lösungen, die Ac-Di-Sol® als Superdisintegrator für eine schnelle Auflösung bieten.
2. Portfolio für kontrollierte Freisetzung, einschließlich METHOCEL™ HPMC, ETHOCEL™ Ethylcellulose für wasserfeste Beschichtungen und POLYOX™ Polyethylenoxid für hochquellende Matrizen.
3. Niedrig-Nitrit-Lösungen, einschließlich Avicel® PH LN und niedrig-nitrit METHOCEL™, die darauf ausgelegt sind, die Risiken der Nitrosaminbildung in festen oralen Dosierungen zu reduzieren und die regulatorischen Standards Japans zu erfüllen.
- Expansion of product portfolio with new low-nitrite solutions meeting strict regulatory requirements
- Strategic entry into growing ODT market with competitive super disintegrant technology
- Development of comprehensive controlled release portfolio addressing multiple drug delivery needs
- None.
Global Leading Excipient Supplier to Highlight Innovations in Oral Disintegrating Tablets, Controlled Release Formulations, and Low-Nitrite Solutions
“IFF Pharma Solutions is committed to redefining drug delivery through material science innovation,” said Frank Zhao, commercial leader, IFF Pharma Solutions,
As a global leading pharmaceutical excipient partner, IFF Pharma Solutions will highlight some of its latest innovations, including:
Oral Disintegrating Tablet (ODT) Solutions
- The ODT market is expanding rapidly, requiring tablets that dissolve quickly for easy administration to children and elderly patients. Incorporating super disintegrants into ODT formulations is essential, as these agents enhance dissolution speed and improve patient compliance. Ac-Di-Sol®, a leading super disintegrant, offers equivalent disintegration efficacy to polyvinylpolypyrrolidone (PVPP).
Controlled Release (C) Portfolio
- METHOCEL™ Hydroxypropyl methylcellulose (HPMC): Enables consistent and controlled delivery of medication, enhancing therapeutic efficacy and patient compliance through customizable HPMC.
- ETHOCEL™ Ethylcellulose: Water-resistant barrier coatings for targeted drug delivery and taste masking in modified-release tablets.
- POLYOX™ Polyethylene Oxide: High-swell matrices for osmotic delivery and abuse-deterrent systems, supporting osmotic pump technology and modified-release matrix formulations.
Low-Nitrite Solutions
- As a low-nitrite microcrystalline cellulose solution, Avicel® PH LN reduces nitrosamine formation risks in oral solid dosages, ensuring compliance with Japan’s stringent regulatory standards.
- IFF Pharma Solutions expands its low-nitrite excipient portfolio by introducing Low Nitrite METHOCEL™, tailored to help mitigate the risk of nitrosamine formation in drugs.
Combining its deep expertise in excipients, innovation capabilities, and regulatory services, IFF Pharma Solutions offers an integrated solutions platform for customer support at every step of their formulation journeys. To learn more about our broad portfolio and proven expertise, visit https://pharma.iff.com.
Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.
©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250324122216/en/
Anson Fan
Regional Communications Specialist
+ 86 13756468374
anson.fan@iff.com
Source: IFF
FAQ
What new products will IFF showcase at CPHI Japan 2025?
When and where will IFF present at CPHI Japan 2025?
What is the purpose of IFF's Low-Nitrite Solutions in pharmaceutical manufacturing?
How does IFF's Ac-Di-Sol® technology compare to traditional disintegrants?
